Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Aug 09, 2022

SELL
$30.71 - $45.71 $52,944 - $78,804
-1,724 Closed
0 $0
Q1 2020

May 26, 2020

BUY
$26.15 - $77.24 $36,139 - $106,745
1,382 Added 404.09%
1,724 $50,000
Q4 2019

Feb 27, 2020

BUY
$60.18 - $154.77 $20,581 - $52,931
342 New
342 $25,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $730M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Verus Capital Partners, LLC Portfolio

Follow Verus Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verus Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verus Capital Partners, LLC with notifications on news.